Dr. Reddy’s launches —Redyx— COVID-19 drug Remdesivir in India

Dr. Reddys Laboratories Ltd on Wednesday announced the launch of Remdesivir, meant for treatment of COVID-19 patients, under a brand name ‘Redyx’ in India. According to a press release from the drug maker, the launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms. “Dr Reddy’s Redyx is available in strength of 100 mg vial,” it said.

Chief Executive Officer of Branded Markets (India and Emerging Markets), Dr Reddys Laboratories, M V Ramana said, “We will continue our efforts to develop products that address significant unmet needs of patients.

The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”

Editor JK News Updates

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

US cancels over 1,000 Chinese visas over possible military links

Thu Sep 10 , 2020
The United States has revoked more than 1,000 visas of Chinese nationals as of this week, a State Department spokeswoman said on Wednesday, as part of the Trump administration’s push to block entry of students and researchers from China it believes have links to the Chinese military. Earlier on  May […]

Breaking News

%d bloggers like this: